Redeye: Promore Pharma - Uncertainty around PXL01 Phase III development in the U.S.

Promore Pharma announced on January 2nd that Cellastra, their intended partner for the Phase III development of PXL01 in North America, did not meet their fundraising goal and hence did not opt in on the collaboration.

Read more and download the Research Update, with a new fair value range:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.